📊 Score Breakdown
Offering Ability
100
Cash Runway
65
Float Risk
7
Warrant Exposure
15
Convertible Debt—
🌦️ Dilution Forecast
⛈️
Warning
High probability of dilution event
58%
🔄 Reverse Split
65%
• 50-day avg $0.58 below $1 exchange minimum
• 8 months cash with weak price
💰 Capital Raise
53%
• Under 12 months cash (8mo)
• Active shelf registration ($20M, 343% of market cap)
📉 Score Deterioration
50%
• Score rose 46 points recently (worsening)
• Score in HIGH risk zone (65/100)
💹 Market Data
Market Cap$5.84M
Shares Outstanding12.69M
Float10.30M
Cash$11.66M
Debt$23.59M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↓ 13.4% shares (2025Q4 vs prior)
27 institutional holders · 1.41M shares
#1
Alyeska Investment Group, L.P.
582.6K shares
#2
Balyasny Asset Management L.P.
464.2K shares
#3
Bleichroeder LP
86.5K shares
+ 17 more holders Sign up free to view →
📉 Short Interest
Short Interest79.5K
Days to Cover1.0
% of Float0.8%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL WARRANT
Dec 31, 2025
xbrl
XBRL CONVERTIBLE
Mar 31, 2024
424B3
ATM
Feb 10, 2026
EFFECT
EFFECT
Feb 09, 2026
8-K
8K EVENT
Feb 02, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for XAIR
📊 XAIR FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 XAIR Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.